March 21, 2022 – The U.S. FDA has approved Keytruda® (pembrolizumab) to treat advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) in patients who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. An FDA-approved test must confirm MSI-H or dMMR status.

• This is Keytruda’s fourth indication to treat gynecological Originally FDA approved in 2014, Keytruda holds more than 30 indications to treat various types of cancer.
• Recommended dosing for endometrial carcinoma is 200mg administered by intravenous infusion once every three weeks or 400mg once every six weeks, for up to 24 months or until disease progression or unacceptable toxicity occur.